insomnia
INSOMNIA

Insomnia can be either having difficulty in initiating sleep, maintaining sleep or experiencing early morning awakening wherein returning to sleep is not easily attained.

These disturbances can cause significant distress and impairment in daytime functioning.

It is the most prevalent sleep disorder in the general population thus accurate diagnosis and effective treatment is necessary.

Diagnosis

  • Based on DSM-5 criteria, a diagnosis of insomnia is made if there is a predominant complaint of dissatisfied sleep related to its quantity or quality associated with at least one of the following symptoms:
    • Having trouble with sleep initiation or maintenance; in children, this is manifested as having trouble with sleep without the caregiver’s intervention
    • Interrupted sleep (eg frequent awakenings or early-morning awakening) with difficulty returning to sleep afterwards
  • Also, DSM-5 criteria stated that the sleeping difficulty:
    • Causes distress or impairment in significant areas of functioning (eg social, occupational, educational, academic, behavioral)
    • Occurs ≥3 nights per week
    • Last for ≥3 months
    • Occurs even though there is sufficient opportunity for sleep
  • The insomnia is not due to & does not happen during another sleep-wake disorder (eg narcolepsy, a breathing-related sleep disorder, a circadian rhythm sleep-wake disorder, a parasomnia)
  • The symptoms are not caused by effects of substance or medication
  • The disturbance is not associated with coexisting mental disorders & medical conditions
  • May specify insomnia if with non-sleep disorder mental comorbidity, with other medical comorbidity or with other sleep disorder
  • Insomnia may be specified further as:
    • Episodic where symptoms occur for at least a month but less than 3 months
    • Persistent where symptoms occur for ≥3 months
    • Recurrent where ≥2 episodes occur within a span of a year
  • Insomnia lasting for <3 months that meets the criteria for insomnia disorder in regards to frequency, intensity, significant distress &/or impairment should be considered under the other specified insomnia disorder

Evaluation

Evaluation

  • Comprehensive clinical history & physical examination that evaluates sleep & waking function of the patient
    • Sleep history includes sleep habits, sleep environment, work schedules, circadian factors
    • Determine the onset, duration, frequency, severity, course & perpetuating factors
    • Ask about past & current treatments & response of the patient
  • Common medical, psychiatric, & medication/substance-related comorbidities should also be assessed
  • Self-administered questionnaires, sleep log, symptom checklists, psychologic screening tests & interviews with bed partner are some of the instruments that help arrive at the proper diagnosis
  • Polysomnography can be used:
    • To evaluate other suspected sleep disorders (ie periodic limb movement disorder)
    • In treatment-resistant insomnia
    • For professional at-risk populations
    • When substantial sleep state misperception is suspected

Classification

Short-Term Insomnia Disorder

  • Symptoms are present for <3 months
  • Also referred to as adjustment insomnia or acute insomnia
  • Presence of insomnia associated with an identifiable stressor
  • Sleep disturbance has a relatively short duration, occurring days to weeks, & is expected to resolve when the stressor resolves or when individual is able to adapt
  • Associated with unfamiliar sleep environment, situational stress, acute medical illness or pain, shift work, or caffeine or alcohol use
  • Diagnosis can only be firmly made retrospectively after it has been relieved
  • Usually triggered by: Changes in sleep environment, high arousal states, poor sleep hygiene, short-term circadian rhythm disorders including particularly by jet lag & rotating shift work

Chronic Insomnia Disorder

  • Insomnia persisting for at least 3 months with a frequency of at least 3 times per week
  • Consists of the former terms primary insomnia, secondary insomnia & comorbid insomnia
  • Patients with chronic insomnia should be evaluated for depression

Risk Factors

  • Increasing age
  • Female gender
  • Medical & psychiatric disease (eg depression, mood disorders)
  • Socioeconomic factors (eg marital separation, unemployment, lower quality of life)

Common Comorbid Medical Disorders & Conditions

  • Neurological
    • Stroke, Parkinson’s disease, dementia, seizure disorders, headache disorders, traumatic brain injury, chronic pain disorders, peripheral neuropathy, neuromuscular disorders
  • Cardiovascular
    • Angina, congestive heart failure
  • Pulmonary/Respiratory
    • Chronic obstructive pulmonary disease (COPD), emphysema, asthma, laryngospasm
  • Gastrointestinal
    • Reflux, peptic ulcer disease, cholelithiasis, colitis, irritable bowel syndrome
  • Genitourinary
    • Incontinence, benign prostatic hypertrophy, interstitial cystitis
  • Endocrine
    • Hyperthyroidism, hypothyroidism, diabetes mellitus
  • Musculoskeletal
    • Rheumatoid arthritis, osteoarthritis, fibromyalgia, Sjogren syndrome, kyphosis
  • Reproductive
    • Pregnancy, menopause, menstrual cycle variations
  • Sleep disorders
    •  Obstructive sleep apnea, central sleep apnea, restless legs syndrome, periodic limb movement disorder, circadian rhythm sleep disorders, parasomnias

Common Comorbid Psychiatric Disorders

  • Mood disorders
    • Major depressive disorder, bipolar mood disorder
  •  Anxiety disorders
    •  Generalized anxiety disorders, panic disorder, posttraumatic stress disorder, obsessive-compulsive disorder
  • Psychotic disorders
    • Schizophrenia, schizoaffective disorder
  •  Amnestic disorders
    • Alzheimer’s disease, other dementias
  • Other disorders
    • Attention-deficit disorder, adjustment disorders, personality disorders, bereavement, stress

Common Medications or Substances Contributing to Insomnia

  • Antidepressants
    • Fluoxetine, Paroxetine, Sertraline, Venlafaxine, Duloxetine, monoamine oxidase inhibitors
  • Stimulants
    • Caffeine, Methylphenidate, amphetamine derivatives, Ephedrine & derivatives, cocaine
  • Decongestants
    • Pseudoephedrine, Phenylephrine, Phenylpropanolamine
  • Narcotic analgesics
    • Oxycodone, Codeine
  • Cardiovascular medications
    • Beta-blockers, alpha-receptor agonists & antagonists, diuretics, lipid-lowering agents
  • Respiratory medications
    • Theophylline, albuterol
  • Alcohol
  • Corticosteroids

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Psychiatry - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 4 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 5 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
14 Sep 2019
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.